TSHA
Taysha Gene Therapies Inc
NASDAQ: TSHA · HEALTHCARE · BIOTECHNOLOGY
$6.39
+1.91% today
Updated 2026-04-30
Market cap
$1.80B
P/E ratio
—
P/S ratio
184.35x
EPS (TTM)
$-0.34
Dividend yield
—
52W range
$2 – $7
Volume
2.8M
Taysha Gene Therapies Inc (TSHA) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Total assets | $15000.00 | $258.88M | $213.96M | $126.28M | $172.73M | $160.36M |
| Cash & equivalents | — | — | — | — | — | — |
| Current assets | $15000.00 | $257.88M | $159.60M | $96.42M | $149.87M | $142.13M |
| Total liabilities | $150000.00 | $7.58M | $118.57M | $125.33M | $97.79M | $88.84M |
| Current liabilities | $150000.00 | $7.13M | $51.75M | $62.79M | $36.76M | $26.23M |
| Long-term debt | — | — | $37.19M | $37.97M | $40.51M | $43.94M |
| Shareholder equity | — | — | — | — | — | — |
| Retained earnings | $-1.11M | $-61.13M | $-235.65M | $-401.44M | $-513.01M | $-602.30M |
| Accounts receivable | — | — | — | — | — | — |
| Inventory | — | — | — | — | — | — |
| Goodwill | — | — | — | — | — | — |